PTIX · Protagenic Therapeutics, Inc.\new
$0.57
-0.17 (-22.97%)
At close · Jan 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The Company expects that additional capital may be required during the next 12 months to continue executing its business plan and to meet its obligations as they become due. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.45M
Shares
1.81M
Volume · Jan 5
580.9K
Avg daily vol (3M)
120.04K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.57
Open$0.32
Day$0.26–0.61
52W close$0.57–11.10
Avg vol 30d172K
Short int13K · 0.7% float · 1.0d
Short vol29%
Last earningsMar 31, 2023
DataApr 2021–Jan 2026
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
Date not confirmed
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
$5.46M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.4
Trailing earnings · reciprocal yield 250.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$565,985
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-51.1%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−82%
below
Price vs 50-day avg
−70%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−66%
trailing
6-month return
−84%
trailing
YTD return
−56%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Flat
1 of 2 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$30.7K over 90 days · 0% sells
Short interest
Rising
0.73% of float · ▲ +0.1% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Fundamentals
EPS growth
+188%
Y/Y
Free cash flow
$-2.8M
Quant / Vol
risk profile
Volatility
322%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
38.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−82%
Bearish
Price vs 50-day avg
−70%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Flat
1 of 2 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$30.7K over 90 days · 0% sells
Short interest
Rising
0.73% of float · ▲ +0.1% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $11
vs 200-day avg -82%
vs 50-day avg -70%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTIX
this stock
Protagenic Therapeutics, Inc.\new
|
$1.45M | -56.2% | — | — | 0.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
2
- % held
- 3.7%
- Reported
- 1 of 2
- Top holder
- DRW Securities, LLC
Held
Float
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTIX | -57.0% | -66.1% | -83.6% | -56.2% | -56.2% |
| SPY | -0.4% | +0.5% | +10.5% | +0.9% | +0.9% |
| vs SPY | -56.6% | -66.6% | -94.2% | -57.0% | -57.0% |